Y Intercept Hong Kong Ltd Invests $570,000 in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Key Points

• Y Intercept Hong Kong Ltd has acquired 20,103 shares of Smith & Nephew SNATS, Inc., valued at approximately $570,000, in the first quarter.
• Several hedge funds have significantly increased their holdings in Smith & Nephew SNATS, with Hara Capital LLC growing its position by 391.4% in the fourth quarter.
• Wall Street analysts currently rate Smith & Nephew SNATS as a "hold" and have set an average price target of $28.00, following recent adjustments by HSBC and Canaccord Genuity Group.

Y Intercept Hong Kong Ltd acquired a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 20,103 shares of the medical equipment provider's stock, valued at approximately $570,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Gallacher Capital Management LLC boosted its holdings in shares of Smith & Nephew SNATS by 10.0% in the first quarter. Gallacher Capital Management LLC now owns 9,983 shares of the medical equipment provider's stock valued at $283,000 after acquiring an additional 907 shares in the last quarter. BKM Wealth Management LLC lifted its position in Smith & Nephew SNATS by 15.4% in the 1st quarter. BKM Wealth Management LLC now owns 21,991 shares of the medical equipment provider's stock worth $624,000 after buying an additional 2,936 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in shares of Smith & Nephew SNATS by 5.4% during the 1st quarter. Bleakley Financial Group LLC now owns 18,653 shares of the medical equipment provider's stock valued at $529,000 after purchasing an additional 949 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Smith & Nephew SNATS by 19.5% during the 1st quarter. New York State Common Retirement Fund now owns 291,148 shares of the medical equipment provider's stock valued at $8,260,000 after purchasing an additional 47,567 shares in the last quarter. Finally, Cerity Partners LLC raised its holdings in shares of Smith & Nephew SNATS by 207.3% during the 1st quarter. Cerity Partners LLC now owns 31,020 shares of the medical equipment provider's stock valued at $880,000 after purchasing an additional 20,926 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company's stock.

Wall Street Analysts Forecast Growth

SNN has been the topic of several recent analyst reports. Hsbc Global Res downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Canaccord Genuity Group upped their price objective on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Finally, HSBC lowered shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $28.00.

Smith & Nephew SNATS Price Performance

Shares of Smith & Nephew SNATS stock traded down $0.48 during midday trading on Monday, hitting $31.19. 531,041 shares of the company traded hands, compared to its average volume of 1,050,749. The stock has a market cap of $13.66 billion, a price-to-earnings ratio of 14.44, a PEG ratio of 0.97 and a beta of 0.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.33 and a current ratio of 2.89. The firm's fifty day moving average price is $29.80 and its 200-day moving average price is $27.97. Smith & Nephew SNATS, Inc. has a 12 month low of $23.69 and a 12 month high of $31.84.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.